دورية أكاديمية
The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study ; Efectividad de guselkumab en pacientes con hidradenitis supurativa en condiciones de práctica clínica: estudio retrospectivo y multicéntrico en España
| العنوان: | The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study ; Efectividad de guselkumab en pacientes con hidradenitis supurativa en condiciones de práctica clínica: estudio retrospectivo y multicéntrico en España |
|---|---|
| المؤلفون: | Rivera-Díaz, R, Pozo, T, Alfageme, F, Díaz Ley, B, Osorio G.F, Chico, R, Romaní, Jorge |
| المساهمون: | Rivera-Díaz R Department of Dermatology, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain. Pozo T Department of Dermatology, Hospital Rio Hortega, Valladolid, Spain. Alfageme F Department of Dermatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid,Spain. Díaz Ley B Department of Dermatology, Hospital Universitario del Sureste, Arganda, Madrid, Spain. Osorio GF Department of Dermatology, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Sevilla, Spain. Chico R Department of Dermatology, Hospital Infanta Sofía, Alcobendas, Madrid, Spain. Romaní J Department of Dermatology, Hospital General de Granollers, Granollers, Spain, Hospital General de Granollers |
| المصدر: | Scientia |
| بيانات النشر: | Elsevier España |
| سنة النشر: | 2023 |
| مصطلحات موضوعية: | Pell - Malalties, Medicaments - Eficàcia, Medicaments dermatològics, DISEASES::Bacterial Infections and Mycoses::Bacterial Infections::Skin Diseases, Bacterial::Hidradenitis Suppurativa, HEALTH SURVEILLANCE::Health Surveillance of Products::Drug and Narcotic Control::Pharmaceutical Preparations::Biological Products, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Case-Control Studies::Retrospective Studies, ENFERMEDADES::infecciones bacterianas y micosis::infecciones bacterianas::enfermedades cutáneas bacterianas::hidradenitis supurada, VIGILANCIA SANITARIA::control sanitario de productos::control de medicamentos y estupefacientes::preparados farmacéuticos::productos biológicos, TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de casos y controles::estudios retrospectivos |
| الوصف: | Biologics; Hidradenitis suppurativa; Guselkumab ; Productos biológicos; Hidradenitis supurativa; Guselkumab ; Biològics; Hidradenitis supurativa; Guselkumab ; Background: Hidradenitis suppurativa (HS) is a chronic skin condition causing lesions in which high levels of interleukin (IL)-23 and T-helper 17 cells are found. Adalimumab remains the only approved treatment. Guselkumab, an antibody targeting the p19 protein subunit of extracellular IL-23, is approved for the treatment of moderate-severe psoriasis, but evidence on its efficacy in treating HS is limited. Objectives: To assess the effectiveness and safety of guselkumab in treating moderate-severe HS under clinical practice conditions. Methods: A multicentre retrospective observational study was carried out in 13 Spanish Hospitals including adult HS patients treated with guselkumab within a compassionate use programme (March 2020-March 2022). Data referred to patient demographic and clinical characteristics at treatment initiation (baseline), patient-reported outcomes (Numerical Pain Rating Scale [NPRS] and Dermatology Life Quality Index [DLQI]), physician scores (International Hidradenitis Suppurativa Severity Score System [IHS4], HS Physical Global Score [HS-PGA] and Hidradenitis Suppurativa Clinical Response [HiSCR]) were recorded at baseline and at 16, 24, and 48 weeks of treatment. Results: A total of 69 patients were included. Most (84.10%) had severe HS (Hurley III) and had been diagnosed for over ten years (58.80%). The patients had been subjected to multiple non-biological (mean 3.56) or biological (mean 1.78) therapies, and almost 90% of those treated with biologics had received adalimumab. A significant decrease in IHS4, HS-PGA, NPRS, and DLQI scores was observed from baseline to 48 weeks of guselkumab treatment (all p<0.01). HiSCR was achieved in 58.33% and 56.52% of the patients at 16 and 24 weeks, respectively. Overall, 16 patients discontinued treatment, mostly due to inefficacy (n=7) or loss of efficacy (n=3). No serious adverse events ... |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 37331620 |
| العلاقة: | Actas Dermo-Sifiliográficas;114(9); https://doi.org/10.1016/j.ad.2023.06.013Test; Rivera-Díaz R, Pozo T, Alfageme F, Díaz Ley B, Osorio GF, Chico R, et al. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study. Actas Dermosifiliogr. 2023 Oct;114(9):755-762.; https://hdl.handle.net/11351/11181Test |
| DOI: | 10.1016/j.ad.2023.06.013 |
| الإتاحة: | https://doi.org/10.1016/j.ad.2023.06.013Test https://hdl.handle.net/11351/11181Test |
| حقوق: | Attribution-NonCommercial-NoDerivatives 4.0 International ; http://creativecommons.org/licenses/by-nc-nd/4.0Test/ ; info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.8B706095 |
| قاعدة البيانات: | BASE |
| تدمد: | 37331620 |
|---|---|
| DOI: | 10.1016/j.ad.2023.06.013 |